Allogeneic blood transfusions have been reported to induce immunomodulation in recipients of blood products. While the mechanism(s) of this immunomodulatory effect is unknown, it has been suggested that this effect of allogeneic blood transfusions could adversely affect patients with a malignant disorder. These concerns have been supported by a number of nonrandomized, mainly retrospective, clinical studies which indicate that allogeneic blood transfusions can adversely affect prognosis following the surgical treatment of oncology patients. Recently, we have shown that allogeneic blood transfusions enhance primary tumor growth and increase metastatic pulmonary nodule formation in inbred mice. The tumor growth-promoting activity of allogeneic blood transfusions was studied also using outbred rabbits. In this present study, we demonstrate that MMUNE SUPPRESSION has been reported to be a con-I sequence of allogeneic blood transfusions. '-' While the mechanism(s) ofthis immunomodulation has not been clearly established, this effect of allogeneic blood transfusion has been used advantageously in clinical renal transplantation and in the treatment ofwomen with recurrent abortion^.^.^ In 198 1, concern was raised that this immunomodulatory effect of allogeneic blood transfusion might adversely affect patients with a malignant disorder.' A number of nonrandomized, mostly retrospective, clinical studies indicate that blood transfusion can adversely affect prognosis following the surgical treatment of patients with a variety of malignant disorders. '*'m2
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Recently, we reported data from inbred experimental animals (mice) indicating that tumor burden was an important factor for the allogeneic blood transfusion-associated enhancement of tumor growth.13-" Specifically, we provided evidence that low tumor burden was associated with enhanced tumor growth, whereas high tumor burden was not. This allogeneic blood transfusion enhanced tumor growth-promoting effect was demonstrated both for solid tumor growth and in an increase in the number of metastatic pulmonary nodules. In order to generalize our previous observations, the tumor growth-promoting effect of allogeneic blood transfusions was further demonstrated in outbred rabbits. We show also that the allogeneic blood transfusion tumor growth-promoting effect can be passively transferred to naive animals (both mice and rabbits) using spleen cells from allogeneically transfused animals. In these experiments, numbers of metastatic pulmonary nodules were significantly increased in both mice and rabbits that had received spleen cells from allogeneically transfused animals compared with those that had received spleen cells from syngeneically transfused animals, or from animals that had been transfused with leukodepleted allogeneic blood. To ascertain the mechanism of the tumor growth-promoting effect, we determined the effect of leukodepleting the allogeneic blood before transfusion. In addition, we examined whether this effect could be passively transferred to naive animals using spleen cells from allogeneically transfused animals. Evidence is provided, in both animal models, that the tumor growth-promoting effect of allogeneic blood transfusions can be abolished by leukodepleting the blood before transfusion; and that this effect can be passively transferred to naive animals, using spleen cells from allogeneically transfused animals.
MATERIALS AND METHODS
Efect of blood transfusions on numbers qf metastatic pulmonary nodules in mice. Adult male mice of the C57B1/6J (H-2b) and the BALB/c (H-2d) strains were purchased from the Jackson Laboratory (Bar Harbor, ME). Only male animals were used in these studies to avoid the potential confounding problem of alloimmunization due to a pregnancy. Blood was collected from both strains of mice, into preservative free heparin ( I U/mL), and transfused intravenously directly into the tail vein of recipient C57B1/6J animals, within an hour of c o l l e~t i o n . '~.~~~'~ Recipient C57B1/6J mice were transfused with 0.2 mL of fresh whole syngeneic (C57BI/6J), allogeneic (BALB/ c), or leukodepleted allogeneic (C57B1/6J) blood, on two occasions (days 0 and 3). Leukodepletion of the allogeneic blood was accomplished using second generation leukocyte filters (Leukotrap Red Cell Storage System; Cutter Biological, Berkeley, CA), as described previously for rabbits." Each filter consists of cellulose acetate fiber in a polycarbonate housing.18 Appropriate filters with I to 5 mL capacity were constructed specifically for these studies by Miles, Inc (Berkeley, CA). On day IO, an intravenous infusion of 2.5 X IO' methylcholanthrene-induced fibrosarcoma (FSL-10) cells, which are syngeneic (H-2b) to C57BI/6J mice, were administered to recipient mice."~"~19 These animals were lulled 2 1 days later, and the number of metastatic pulmonary nodules counted, as described previo~sly.'~.'~ In all experiments, the enumeration of the pulmonary metastatic nodules was performed by an individual who had no knowledge of the source of the blood product received by that animal.
Eflect of blood transfusions on numbers of metastatic pulmonary nodules in rabbits. Two different outbred strains of rabbits were used for these studies. California Black (CB) rabbits were used as the allogeneic blood donors and New Zealand White (NZW) rabbits were Again, only male animals were used in all experiments, to avoid the potential confounding problem of alloimmunization due to a pregnancy. Blood was collected, prepared, and administered as described previously." In these experiments, subject NZW rabbits received two intravenous infusions of either syngeneic (NZW) blood, allogeneic (CB) blood, or leukodepleted allogeneic (NZW) blood before receiving an intravenous infusion of VX-2 tumor cells, obtained and propagated as reported by Stetson et al.*O In these experiments, I5 mL of blood was administered intravenously on each of days 0 and 3. On day IO, lo5 VX-2 tumor cells were intravenously administered via a marginal ear vein to recipient NZW rabbits. Twenty-eight days later the animals were killed and the number of metastatic pulmonary nodules counted, as described for the murine experiments. Again, the enumeration of the pulmonary metastatic nodules was performed by an observer without knowledge of the treatment received by that animal.
Effect of the passive transfer of spleen cells to naive animals on the development ofpulmonary metastases.
In these experiments, C57BI/ 65 mice or NZW rabbits were transfused using the protocols described above with syngeneic, allogeneic, or leukodepleted allogeneic blood. In both the murine and rabbit spleen cell transfer experiments, the recipient animals were killed on day 10 following transfusion, and the spleens removed. Spleen cell suspensions were obtained by disrupting the intact spleens through a tissue sieve into a sterile dish containing sterile phosphate buffered saline (pH 7.4). Spleen cells from transfused animals were then administered intravenously (1 O6 in the murine experiments and 20 X IO6 in the rabbit experiments) into naive nontransfused animals. Sixty to ninety minutes later, each of these animals received an intravenous inoculation of tumor cells; 2.5 X lo5 FSL-10 cells in the case of mouse experiments and lo5 VX-2 cells in the rabbit experiments. The mice were killed 2 I days and the rabbits 28 days later; following which the numbers of metastatic pulmonary nodules were counted as described above.
RESULTS

Effect of blood transfusions on numbers ofpulmonary metastases in mice.
The leukodepletion of the mouse blood produced a mean leukocyte count reduction of 99.6% from 2.748 to 0.012 X 109/L. Pooled data from three separate experiments are shown in Table 1 . Each experiment provided similar data. A statistically significant increase in the number of pulmonary metastatic nodules was seen in animals that had received allogeneic whole blood as compared with those animals that had received syngeneic whole blood (P = .01) or received leukodepleted allogeneic blood (P = .0002). The numbers of pulmonary metastases in those mice that had received leukodepleted allogeneic blood was the same as in mice that had received syngeneic blood. Efect of allogeneic blood transfusion on numbers of pulmonary metastases in rabbits. The leukodepletion of the rabbit fresh whole blood was 99.8% effective (mean leukocyte count reduction: 4.595 to 0.009 X 109/L). In the rabbit model, allogeneic whole blood also caused a significant (P = .Ol) enhancement in the number of metastatic pulmonary nodules observed, when compared with rabbits that had received syngeneic whole blood (see Table 2 ). The leukodepletion of the allogeneic whole blood, before its transfusion, also resulted in a significant (P = .OOOl) amelioration of the effect of the allogeneic blood transfusion.
The effect of the transfev of spleen cells on the observed numbers of pulmonary metastatic nodules. Table 3 shows the results of three spleen cell transfer experiments from transfused mice to naive animals. In these experiments, the numbers of metastatic nodules were significantly increased in those mice that had received spleen cells from allogeneically transfused animals, compared with those that had received spleen cells from syngeneically transfused animals (P = .OOO l), or from animals that had been transfused with leukodepleted allogeneic blood (P = .0006).
Similar data were obtained in an experiment in which spleen cells from allogeneically transfused rabbits (n = 12 per group) were passively transferred to naive rabbits (data not shown). In this experiment, the number of metastatic nodules in rabbits that had received spleen cells from allogeneically transfused animals were significantly greater (P = .0015) than those that had received spleen cells from syngeneically transfused animals. The present data, from both inbred and outbred animal models, demonstrate that the tumor growth-promoting effect of allogeneic blood transfusion is mediated by donor leukocytes. Thus, the tumor growth-promoting effect of allogeneic blood transfusion is ameliorated by the removal of the donor allogeneic leukocytes before transfusion. In addition, the results show that this effect can be passively transferred to naive animals using spleen cells from allogeneically transfused animals. These data suggest that the tumor growthpromoting effect of allogeneic blood transfusions is mediated immunologically.
Immunological mechanisms have been proposed previously to explain the enhanced renal allograft survival seen in patients undergoing allogeneic renal transplantation.4,5,9,2',22 This postulated immunomodulatory effect of allogeneic leukocytes has also been used advantageously in clinical transplantation and the treatment of women with spontaneous recurrent abortion^.^-^.^' We extend these observations to clearly demonstrate that this immunomodulatory effect is also operable in patients with a malignancy. This is the first report that demonstrates clearly that the tumor growth-promoting effect of allogeneic blood transfusion is related to the presence of donor leukocytes in the allogeneic blood. These data therefore provide new insights into the mechanism of the tumor growth-promoting effect of allogeneic blood transfusions. More importantly, it provides information as to how to potentially ameliorate this deleterious effect.
A number of reports have provided evidence for the deletqieus effyts of allogeneic blood transfusions o n the recurrence of'a malignancy in patients undergoing curative s~r g e r y . ' ,~,~-'~ The results of the present study indicate that this deleterious effect on tumor recurrence might be avoided by the leukodepletion of the allogeneic blood before transfusion. Although the amelioration, by leukodepletion, of tumor growth has not yet been reported in humans, a recent prospective randomized study demonstrated a statistically significant abrogation of the incidence of postoperative infection in colorectal cancer patients who received leukodeleted blood, compared with those that received nonleukodepleted blood.23 Thus, while data from experimental animals cannot necessarily be extrapolated to the clinical situation, these present studies suggest that patients with a malignant disorder are likely to benefit from the transfusion of leukodepleted blood products, to avoid the potential deleterious tumor growth-promoting effect of allogeneic blood transfusions. 
